213 related articles for article (PubMed ID: 37439680)
1. Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Traphagen NA; Schwartz GN; Tau S; Roberts AM; Jiang A; Hosford SR; Marotti JD; Goen AE; Romo BA; Johnson AL; Duffy EK; Demidenko E; Heverly P; Mosesson Y; Soucy SM; Kolling F; Miller TW
Clin Cancer Res; 2023 Sep; 29(18):3717-3728. PubMed ID: 37439680
[TBL] [Abstract][Full Text] [Related]
2. Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer.
Traphagen NA; Schwartz GN; Tau S; Jiang A; Hosford SR; Goen AE; Roberts AM; Romo BA; Johnson AL; Duffy EK; Demidenko E; Heverly P; Mosesson Y; Soucy SM; Kolling F; Miller TW
bioRxiv; 2023 Mar; ():. PubMed ID: 36993590
[TBL] [Abstract][Full Text] [Related]
3. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis.
Kim H; Tarhuni A; Abd Elmageed ZY; Boulares AH
J Transl Med; 2015 Jul; 13():233. PubMed ID: 26183824
[TBL] [Abstract][Full Text] [Related]
5. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies.
Carter J; Hulse M; Sivakumar M; Burtell J; Thodima V; Wang M; Agarwal A; Vykuntam K; Spruance J; Bhagwat N; Rager J; Ruggeri B; Scherle P; Ito K
Cancer Res Commun; 2023 Nov; 3(11):2233-2243. PubMed ID: 37861290
[TBL] [Abstract][Full Text] [Related]
6. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
7. PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells.
Gadad SS; Camacho CV; Malladi V; Hutti CR; Nagari A; Kraus WL
Mol Cancer Res; 2021 Oct; 19(10):1688-1698. PubMed ID: 34158394
[TBL] [Abstract][Full Text] [Related]
8. Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer.
Saatci O; Cetin M; Uner M; Tokat UM; Chatzistamou I; Ersan PG; Montaudon E; Akyol A; Aksoy S; Uner A; Marangoni E; Sajish M; Sahin O
Nat Commun; 2023 Nov; 14(1):6997. PubMed ID: 37914699
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells.
Patki M; Salazar Md; Trumbly R; Ratnam M
Biochem Biophys Res Commun; 2015 Feb; 457(3):404-11. PubMed ID: 25582774
[TBL] [Abstract][Full Text] [Related]
10. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
[TBL] [Abstract][Full Text] [Related]
11. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
Ibrahim YH; García-García C; Serra V; He L; Torres-Lockhart K; Prat A; Anton P; Cozar P; Guzmán M; Grueso J; Rodríguez O; Calvo MT; Aura C; Díez O; Rubio IT; Pérez J; Rodón J; Cortés J; Ellisen LW; Scaltriti M; Baselga J
Cancer Discov; 2012 Nov; 2(11):1036-47. PubMed ID: 22915752
[TBL] [Abstract][Full Text] [Related]
12. PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer.
Ghosh M; Kang MS; Katuwal NB; Hong SD; Jeong YG; Park SM; Kim SG; Moon YW
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069409
[TBL] [Abstract][Full Text] [Related]
13. 2,3,7,8-Tetrachlorodibenzo-p-dioxin modulates the induction of DNA strand breaks and poly(ADP-ribose) polymerase-1 activation by 17beta-estradiol in human breast carcinoma cells through alteration of CYP1A1 and CYP1B1 expression.
Lin PH; Lin CH; Huang CC; Fang JP; Chuang MC
Chem Res Toxicol; 2008 Jul; 21(7):1337-47. PubMed ID: 18558727
[TBL] [Abstract][Full Text] [Related]
14. Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
Schoonen PM; Talens F; Stok C; Gogola E; Heijink AM; Bouwman P; Foijer F; Tarsounas M; Blatter S; Jonkers J; Rottenberg S; van Vugt MATM
Nat Commun; 2017 Jul; 8():15981. PubMed ID: 28714471
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
16. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of PARP inhibitors in breast cancer.
Pandya K; Scher A; Omene C; Ganesan S; Kumar S; Ohri N; Potdevin L; Haffty B; Toppmeyer DL; George MA
Breast Cancer Res Treat; 2023 Jul; 200(1):15-22. PubMed ID: 37129747
[TBL] [Abstract][Full Text] [Related]
19. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
20. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
